SEC Form 4
Black Diamond Therapeutics, Inc. (BDTX) insider trading
No open-market BDTX insider purchases or sales were filed in the 12 months to Oct 26, 2026.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $0
- 0 filings
Who traded BDTX, and when
BDTX daily close from Oct 27, 2025 to Oct 26, 2026, between $1.61 and $4.87, last $1.69. No open-market insider purchases or sales were filed in this period.
No open-market insider purchases or sales were filed in the last 12 months.
Open-market trades
0 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | ||||||
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
| No open-market purchases or sales in the last 12 months. | |||||||
GET /stocks/filings/vX/form-4?tickers=BDTX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BDTX"
],
"issuer_cik": "0001701541",
"owner_cik": "0001613867",
"accession_number": "0001193125-26-396868",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-18",
"issuer_name": "Black Diamond Therapeutics, Inc.",
"issuer_trading_symbol": "BDTX",
"owner_name": "Behbahani Ali",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "holding",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"shares_owned_following_transaction": 4448757,
"direct_or_indirect": "I",
"nature_of_ownership": "See Note 3",
"footnotes": [
{
"id": "F3",
"description": "The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."
}
]
},
{
"tickers": [
"BDTX"
],
"issuer_cik": "0001701541",
"owner_cik": "0001613867",
"accession_number": "0001193125-26-396868",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-18",
"issuer_name": "Black Diamond Therapeutics, Inc.",
"issuer_trading_symbol": "BDTX",
"owner_name": "Behbahani Ali",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-18",
"transaction_code": "A",
"equity_swap_involved": false,
"transaction_shares": 7707,
"transaction_price_per_share": 1.93,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 110236,
"transaction_value": 14874.51,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."
},
{
"id": "F2",
"description": "The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 8 records
- Grants and awards8 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Black Diamond Therapeutics, Inc.'s CEO sold stock?
No. Mark A. Velleca (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is BDTX’s insider data?
These are BDTX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BDTX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BDTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.